Abstract
The results presently available from randomised clinical trials and their meta-analysis indicate that Hydroxychloroquine is not associated in COVID-19 patients with either decreased mortality or clinical worsening. Thus, the use of Hydroxychloroquine in COVID-19 patients cannot at present be encouraged. However, the hypothesis that Hydroxychloroquine might have a beneficial role in subgroups of patients at low risk and/or when used at low dosage (≤ 400 mg/day) deserves to be tested in large, well designed randomised clinical trials.
Keywords: COVID-19; Hydroxychloroquine; Infectious disease; Mortality; SARS-CoV-2.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Mortality, Hydroxychloroquine, Infectious disease, 【초록키워드】 Meta-analysis, SARS-CoV-2, Hydroxychloroquine, clinical trials, risk, Infectious disease, randomised clinical trial, Hypothesis, COVID-19 patient, can not, Randomised clinical trials, decreased mortality, dosage, subgroups, worsening, tested, subgroups of patient, 【제목키워드】 Final,
【저자키워드】 COVID-19, SARS-CoV-2, Mortality, Hydroxychloroquine, Infectious disease, 【초록키워드】 Meta-analysis, SARS-CoV-2, Hydroxychloroquine, clinical trials, risk, Infectious disease, randomised clinical trial, Hypothesis, COVID-19 patient, can not, Randomised clinical trials, decreased mortality, dosage, subgroups, worsening, tested, subgroups of patient, 【제목키워드】 Final,
{{{ 추상적인 }}}
현재 무작위 임상 시험 및 메타 분석에서 사용할 수 있는 결과는 하이드록시클로로퀸이 사망률 감소 또는 임상 악화와 관련된 COVID-19 환자와 관련이 없음을 나타냅니다. 따라서 현재로서는 COVID-19 환자에서 하이드록시클로로퀸의 사용을 권장할 수 없습니다. 그러나 하이드록시클로로퀸이 저위험군 및/또는 저용량(≤ 400mg/일)으로 사용되는 환자의 하위 그룹에서 유익한 역할을 할 수 있다는 가설은 잘 설계된 대규모 무작위 임상 시험에서 테스트할 가치가 있습니다.
{{ 키워드: }} 코로나19; 하이드록시클로로퀸; 감염성 질병; 인류; 사스 코로나바이러스 2.